The Latest Cardiac and Vascular News
DANVERS, Mass.–(BUSINESS WIRE)–The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis. Impella […]
Study conducted at 109 hospitals with oversight by 10 Japanese professional societies, including Japanese Circulation Society TOKYO–(BUSINESS WIRE)–A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart pump finds use of Impella is associated with a 77% survival rate […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed, Inc. (NASDAQ: ABMD) announced that on Thursday, August 6, 2020, the Company will release financial results for the first quarter of fiscal 2021. The Company will host a conference call to discuss the results on Thursday, August […]
DANVERS, Mass.–(BUSINESS WIRE)–The first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart recovery. The study was published in the July edition of the American […]
DANVERS, Mass.–(BUSINESS WIRE)–Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI, which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to improve patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD), maker of the Impella heart pump, announced today it has appointed Charles (Chuck) Simonton, M.D., as vice president and chief medical officer. Dr. Simonton is renowned for his leadership in product development and large-scale clinical trials. He was […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company’s investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP™ heart pump. […]
DANVERS, Mass.–(BUSINESS WIRE)–The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism (PE). Abiomed (NASDAQ: ABMD) manufactures Impella RP. Impella RP […]
Women Disproportionately Impacted with Bailout DANVERS, Mass.–(BUSINESS WIRE)–Data from more than 1,000 patients presented during the virtual 2020 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions demonstrates Impella reduced in-hospital mortality when placed before a non-emergent percutaneous coronary intervention (PCI) is […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no […]
